Invention Grant
- Patent Title: Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof
-
Application No.: US16091456Application Date: 2017-04-04
-
Publication No.: US10689452B2Publication Date: 2020-06-23
- Inventor: Roland Kontermann , Klaus Pfizenmaier , Fabian Richter , Kirstin Zettlitz , Peter Scheurich , Andreas Herrmann
- Applicant: UNIVERSITÄT STUTTGART , BALIOPHARM AG
- Applicant Address: DE Stuttgart CH Basel
- Assignee: UNIVERSITÄT STUTTGART,BALIOPHARM AG
- Current Assignee: UNIVERSITÄT STUTTGART,BALIOPHARM AG
- Current Assignee Address: DE Stuttgart CH Basel
- Agency: Meunier Carlin & Curfman LLC
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@296ad745
- International Application: PCT/EP2017/057997 WO 20170404
- International Announcement: WO2017/174586 WO 20171012
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P37/06
Abstract:
The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.
Public/Granted literature
- US20190144555A1 MONOVALENT INHIBITOR OF huTNFR1 INTERACTION Public/Granted day:2019-05-16
Information query
